Synthetic Biologics, Inc (AMEX:SYN) will hold its 3Q20 earnings conference call with the financial community on 10th November 2020 at 4:30 PM Eastern Time.
The conference call will be webcast live on Internet at www.syntheticbiologics.com
Earnings Expectation
Synthetic Biologics, Inc developer of therapeutics microbiome, is expected to report third quarter earnings results, after market close, on Tuesday 10th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.17 per share. Looking ahead, the full year loss are expected at $ 0.65 per share.
Synthetic Biologics, Inc., a clinical stage company, focuses developing therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates include SYN-004 that is in Phase III clinical trial designed to protect the gut microbiome from the effects of commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases, and monoclonal antibody therapies that prevents and treats pertussis.